First-in-Human Mechanical Leaflet Modification of Native Aortic Stenosis During TAVR Authors: Danny Dvir, Amjad Abu Salman, Philippe Taieb, Shemy Carasso, Rami Jubeh, Arik Wolak, Elias Hellou, Michael Glikson, Anna Turyan Published: 2026 ABSTRACT AbstractBackgroundCoronary obstruction is a life-threatening complication of transcatheter aortic valve replacement (TAVR). Mechanical leaflet modification (LM) has been developed to mitigate this risk in patients with degenerated bioprostheses. However, their use in native valves has not previously been reported.Case SummaryWe report 2 cases of mechanical LM performed in patients with severe native aortic stenosis at high risk for coronary obstruction during TAVR. In both cases, successful LM was achieved using a dedicated device (ShortCut, Pi-Cardia), followed by TAVR. Imaging validated leaflet split and preserved coronary flow. After the procedure, the patients had optimal valve hemodynamics without neurological adverse events.DiscussionThese cases demonstrate the technical feasibility of dedicated mechanical LM in native calcific aortic valve disease. This strategy warrants further clinical investigation.NoveltyThis report describes, to our knowledge, the first-in-human application of mechanical LM for native aortic stenosis at risk for coronary obstruction during TAVR.Key words: aortic valve, complication, stenosis Illustration of the Procedure and Main Findings AS = aortic stenosis; TEE = transesophageal echocardiography. Coronary obstruction during transcatheter aortic valve replacement (TAVR) is a potentially catastrophic complication associated with substantial morbidity and mortality.1 Anatomical predictors include low coronary ostial height, narrow sinuses of Valsalva, bulky leaflet calcification, and unfavorable relationships between the native leaflets and coronary ostia.2,3 Current preventive strategies primarily rely on coronary protection with chimney or snorkel stenting.4 Although widely used, these approaches are off-label and do not directly address the underlying mechanism of coronary obstruction, namely displacement of the native or bioprosthetic leaflet toward the coronary ostium after valve implantation. Leaflet modification (LM) has emerged as an alternative strategy designed to prevent coronary obstruction by creating a controlled leaflet split before transcatheter valve deployment or by other mechanisms.5,6 Electrosurgical leaflet laceration and intraleaflet valve deployment techniques have demonstrated effectiveness but remain technically demanding and are not universally adopted.7 ShortCut (Pi-Cardia Ltd) is the first dedicated transfemoral catheter designed to mechanically split aortic valve leaflets before TAVR, preserving coronary inflow.8,9 This device received Food and Drug Administration de novo clearance in September 2024 for the treatment of failed tissue valves, following completion of first-in-human experience and a pivotal multicenter study. To date, reported clinical experience with mechanical LM has been limited to degenerated bioprosthetic valves undergoing valve-in-valve TAVR. We currently report the first 2 human cases of dedicated mechanical LM performed in patients with native calcific aortic stenosis (AS) at high risk for coronary obstruction during TAVR. Case Presentations Patient 1 An 88-year-old woman presented with symptomatic severe AS and NYHA functional class III dyspnea. Transthoracic echocardiography demonstrated a left ventricular ejection fraction of 60%, peak and mean aortic valve gradients of 92 mm Hg and 47 mm Hg, respectively, and an aortic valve area of 0.8 cm2. Preprocedural computed tomography demonstrated a small aortic root anatomy with a perimeter-derived annular diameter of 18.1 mm (Figure 1). The left coronary height measured 10 mm, and the left coronary cusp extended above the anticipated coronary risk plane. The virtual transcatheter heart valve–to-coronary distance was 3.6 mm, indicating high risk for coronary obstruction. The aortic valve calcium score was 793 Agatston units, with a localized calcific deposit within the left coronary cusp measuring 7.3 × 2.8 mm. Computed Tomography Images Before the Procedure of Patient 1 (A) Aortic annulus dimensions. Perimeter-derived diameter of 18.1 mm. (B) Left main coronary ostial height of 10 mm. (C) Left cusp leaflet length of 15 mm. (D) Sinus of Valsalva dimensions. The left coronary ostium seems to emerge below the top of the leaflet commissures. (E) With a 20-mm circle deflection, the virtual THV-to-coronary distance was 3.6 mm. (F) The left coronary ostium has minimal eccentricity within the left coronary cusp. (G) Aortic leaflet calcification assessment. The patient had a calcium score of 793 HU. (H and I) A calcification nodule of 7.3 × 2.8 mm was observed within the left coronary cusp. THV = transcatheter heart valve. Patient 2 An 88-year-old woman with severe pulmonary hypertension (estimated pulmonary artery systolic pressure: 80 mm Hg) and moderate mitral regurgitation presented with pulmonary congestion and NYHA class IV heart failure symptoms. Echocardiography demonstrated a left ventricular ejection fraction of 60%, moderate mitral regurgitation, and severe AS with peak and mean gradients of 60 mm Hg and 37 mm Hg, respectively, and an aortic valve area of 0.7 cm2. Computed tomography demonstrated a small annular anatomy with a perimeter-derived diameter of 21.5 mm (Figure 2). The left coronary height measured 7 mm, and the left coronary cusp extended above the coronary risk plane. The virtual transcatheter heart valve–to-coronary distance was 3.9 mm. The aortic valve calcium score was 1,296 Agatston units, with multiple calcific deposits located within the left coronary cusp. The patient was considered at high risk for coronary obstruction during TAVR. ShortCut Procedure of Patient 1 (A) Baseline transesophageal echocardiogram showing the left coronary cusp (arrow). (B) Selective injection in the left coronary cusp in left side view (LAO-cranial projection). (C) The ShortCut positioning arm is positioned at the base of the left cusp in left side view (LAO-cranial projection). (D) Left cusp front view (RAO-caudal projection) verifies the centricity of the positioning arm. (E) The splitting element (arrow) is activated at the base of the left cusp. (F) Splitting the left cusp (arrow) in process. (G) Transesophageal echocardiogram after leaflet splitting showing a split in the left coronary cusp (arrow). (H) Intentional nonselective coronary injection showing normal coronary flow. LAO = left anterior oblique; RAO = right anterior oblique. Procedural Technique Following approval for compassionate use by the institutional ethics committee, both patients underwent mechanical LM of the left coronary cusp using the ShortCut system on June 11, 2026 (Figures 3 and 4, Video 1, Video 2, Video 3, Video 4, Video 5, Video 6, Video 7, Video 8, Video 9, Video 10, Video 11, Video 12, Video 13, Video 14, Video 15, Video 16, Video 17, Video 18). Procedures were performed under general anesthesia with transesophageal echocardiographic guidance and cerebral embolic protection using the Sentinel system (Boston Scientific). Femoral arterial access was obtained using an 18-F sheath, and all procedures were performed over a Safari XS guidewire (Boston Scientific). A separate 6-F femoral access was used for an AL2 guide catheter that allowed for left cusp contrast injections while we localized the ShortCut device. That catheter was exchanged during TAVR to a conventional pigtail. The ShortCut device was advanced over a standard 0.035-inch guidewire into the ascending aorta. After crossing the native aortic valve, the positioning arm was deployed and aligned with the target leaflet under fluoroscopic guidance. After confirmation of leaflet engagement at its basal attachment, the splitting element was activated to puncture the leaflet from the ventricular aspect. Controlled retraction of the device produced a longitudinal split extending from leaflet base to tip. The device was subsequently removed, and TAVR was performed over the same guidewire. We examined the flow to the left coronary artery after TAVR with nonselective contrast injection. A selective injection was not attempted to not disrupt that leaflet splay with a catheter. Computed Tomography Images Before the Procedure of Patient 2 (A) Aortic annulus dimensions. Perimeter-derived diameter of 21.5 mm. (B) Left main coronary ostial height of 7 mm. (C) Left cusp leaflet length of 15.4 mm. (D) Sinus of Valsalva dimensions. The left coronary ostium seems to emerge below the top of the leaflet commissures. (E) With a 22-mm circle deflection, the virtual THV-to-coronary distance was 3.9 mm. (F) The left coronary ostium has minimal eccentricity within the left coronary cusp. (G) Aortic leaflet calcification assessment. The patient had a calcium score of 1,296 HU. (H and I) Several calcification segments were observed within the left coronary cusp. THV = transcatheter heart valve. ShortCut Procedure of Patient 2 (A) Baseline transesophageal echocardiogram showing the left coronary cusp (arrow). (B) Selective injection in the left coronary cusp in left side view (LAO-cranial projection) while the ShortCut device is delivered in the ascending aorta. (C) The ShortCut positioning arm (arrow) is positioned at the base of the left cusp in left side view (LAO-cranial projection). (D) The splitting element (arrow) is activated at the base of the left cusp. (E) Transesophageal echocardiogram after leaflet splitting showing a split (arrow) in the left coronary cusp. (F) Intentional nonselective coronary injection showing normal coronary flow. LAO = left anterior oblique. Procedural Outcomes In patient 1, mechanical LM was completed successfully in approximately 6 minutes. Angiography and transesophageal echocardiography confirmed complete splitting of the left coronary cusp. TAVR was performed using a 23-mm Evolut FX+ valve (Medtronic) followed by postdilation with an 18-mm balloon. Final echocardiography demonstrated trivial paravalvular regurgitation and residual peak/mean gradients of 19/12 mm Hg. Recovery was uneventful except for a femoral hematoma that did not require intervention. No neurological events or conduction disturbances occurred. In patient 2, hemodynamic instability developed following induction of anesthesia before initiation of LM. Consequently, both LM and TAVR were expedited. Mechanical LM was completed in approximately 2.5 minutes, and successful leaflet splitting was confirmed by angiography and transesophageal echocardiography. TAVR was performed using a 26-mm Evolut valve followed by postdilation with a 20-mm balloon. Final echocardiography demonstrated trivial regurgitation and residual gradients of 12/6 mm Hg. The patient recovered uneventfully with early extubation and without vascular, neurological, or conduction complications. Discussion These first-in-human cases demonstrate the feasibility of dedicated mechanical LM in patients with native calcific AS undergoing TAVR. Native valve anatomy presents unique challenges compared with degenerated surgical or transcatheter bioprosthetic valves. Native leaflets are frequently thicker, more heavily calcified, and exhibit substantial heterogeneity in calcification distribution while their coronary ostia, especially the left, are naturally commissurally aligned.10 Consequently, successful leaflet splitting in native valves could not be assumed based on prior experience in failed bioprosthetic valves. In both patients, mechanical LM resulted in successful splitting of heavily calcified native left coronary cusps without procedural complications. Importantly, LM was followed by successful TAVR without evidence of coronary compromise despite anatomical features associated with high risk for coronary obstruction. These findings suggest that dedicated mechanical LM may represent an attractive alternative to coronary protection strategies based on chimney stenting. Furthermore, mechanical LM may offer procedural simplification compared with electrosurgical leaflet laceration techniques by eliminating the need for electrosurgical equipment and specialized wire traversal techniques. Although encouraging, these observations are limited to 2 cases and short-term follow-up. The efficacy of the ShortCut device in splitting heavily calcified aortic valve leaflets is not guaranteed and should be further evaluated. Additional studies are needed to define procedural success rates, safety outcomes, patient selection criteria, and long-term clinical effectiveness. Future Directions The potential applications of mechanical LM may extend beyond coronary obstruction prevention. Controlled leaflet splitting could facilitate expansion of transcatheter valves in heavily calcified anatomies, improve future coronary access after TAVR, and potentially enable transcatheter aortic root tricuspidization strategies in selected bicuspid aortic valve anatomies.11,12 Prospective studies are warranted to evaluate these hypotheses and to determine the broader role of dedicated mechanical LM in contemporary TAVR practice. Conclusions Dedicated mechanical leaflet modification using the ShortCut system was successfully performed in 2 patients with native calcific AS at high risk for coronary obstruction during TAVR. These first-in-human cases demonstrate procedural feasibility and support further clinical investigation of this novel strategy. Take-Home Messages •Coronary obstruction remains one of the most serious complications of TAVR. Coronary obstruction remains one of the most serious complications of TAVR. •Dedicated mechanical leaflet modification can be successfully performed in selected native aortic valve patients at high risk for coronary obstruction. Dedicated mechanical leaflet modification can be successfully performed in selected native aortic valve patients at high risk for coronary obstruction. •These first-in-human cases support further evaluation of mechanical leaflet modification as an adjunctive strategy during TAVR. These first-in-human cases support further evaluation of mechanical leaflet modification as an adjunctive strategy during TAVR. Funding Support and Author Disclosures Prof Danny Dvir is a consultant to Medtronic, Edwards Lifesciences, Abbott, and Pi-Cardia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1 Patient 1: Baseline Transesophageal Echocardiography Video 2 Patient 1: Baseline Left Cusp Side View (LAO-cranial projection) Video 3 Patient 1: ShortCut Positioning Arm Opened in Left Cusp Side View (LAO-cranial projection) Video 4 Patient 1: ShortCut Positioning Arm Opened in Left Cusp Front View (RAO-caudal projection) Video 5 Patient 1: ShortCut Splitting Element Opened Video 6 Patient 1: ShortCut Left Cusp Leaflet Splitting Video 7 Patient 1: Transesophageal Echocardiogram During Leaflet Splitting Video 8 Patient 1: Transesophageal Echocardiogram After Leaflet Splitting Video 9 Patient 1: New Aortic Regurgitation After Leaflet Split Video 10 Patient 1: Postdilatation With 18-mm Balloon of 23-mm Evolut Video 11 Patient 1: Planned Nonselective Left Coronary Injection Showing Normal Flow Video 12 Patient 2: Baseline Transesophageal Echocardiography Video 13 Patient 2: Baseline Left Cusp Side View (LAO-cranial projection) Video 14 Patient 2: ShortCut Positioning Arm Opened in Left Cusp Front View (RAO-caudal projection) Video 15 Patient 2: ShortCut Left Cusp Leaflet Splitting Video 16 Patient 2: Transesophageal Echocardiogram During Leaflet Splitting Video 17 Patient 2: Transesophageal Echocardiogram After Leaflet Splitting Video 18 Patient 2: Planned Nonselective Left Coronary Injection Showing Normal Flow References Associated Data Supplementary Materials Video 1 Patient 1: Baseline Transesophageal Echocardiography Video 2 Patient 1: Baseline Left Cusp Side View (LAO-cranial projection) Video 3 Patient 1: ShortCut Positioning Arm Opened in Left Cusp Side View (LAO-cranial projection) Video 4 Patient 1: ShortCut Positioning Arm Opened in Left Cusp Front View (RAO-caudal projection) Video 5 Patient 1: ShortCut Splitting Element Opened Video 6 Patient 1: ShortCut Left Cusp Leaflet Splitting Video 7 Patient 1: Transesophageal Echocardiogram During Leaflet Splitting Video 8 Patient 1: Transesophageal Echocardiogram After Leaflet Splitting Video 9 Patient 1: New Aortic Regurgitation After Leaflet Split Video 10 Patient 1: Postdilatation With 18-mm Balloon of 23-mm Evolut Video 11 Patient 1: Planned Nonselective Left Coronary Injection Showing Normal Flow Video 12 Patient 2: Baseline Transesophageal Echocardiography Video 13 Patient 2: Baseline Left Cusp Side View (LAO-cranial projection) Video 14 Patient 2: ShortCut Positioning Arm Opened in Left Cusp Front View (RAO-caudal projection) Video 15 Patient 2: ShortCut Left Cusp Leaflet Splitting Video 16 Patient 2: Transesophageal Echocardiogram During Leaflet Splitting Video 17 Patient 2: Transesophageal Echocardiogram After Leaflet Splitting Video 18 Patient 2: Planned Nonselective Left Coronary Injection Showing Normal Flow